Apellis Pharmaceuticals Inc (APLS) - News Archive

Apellis Pharmaceuticals, Inc. has announced significant new findings regarding EMPAVELI (pegcetacoplan), a complement C3 inhibitor, based on data from the open-label period of the Phase 3 VALIANT study. These findings,...

Apellis Pharmaceuticals and Sobi Unveil Promising EMPAVELI Data Amid Revenue Challenges WALTHAM, Mass. and STOCKHOLM, June 6, 2025 In a significant breakthrough for the treatment of rare kidney diseases, Apellis Pharmac...

In a significant development for patients with rare kidney diseases, Apellis Pharmaceuticals Inc. (NASDAQ: APLS) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Supplemental New Drug Appl...

In a series of strategic moves epitomizing the company’s aggressive recruitment and talent retention strategy, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global leader in biopharmaceutical innovations focusing on c...

Exploring Novel Therapeutic Frontiers: Apellis Pegcetacoplan Takes Centre Stage at ASN Kidney Week In a pivotal revelation for the nephrology community, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has unveiled its late...

Apellis Pharmaceuticals, Inc. has recently been in the spotlight following its pivotal updates concerning pegcetacoplan, an intravitreal injection developed for the treatment of geographic atrophy (GA) secondary to age-...

Apellis Pharmaceuticals, a leading global biopharmaceutical company specializing in complement, recently announced the approval of equity awards for several new employees. These equity awards, granted under Nasdaq Listi...

In a significant advancement for kidney disease treatments, Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Sobi) have jointly announced positive topline results from the Phase 3 VALIANT Study. This groun...

In an era where the pharmaceutical landscape is increasingly driven by groundbreaking innovations, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has emerged as a paradigmatic example. The Waltham, Massachusetts-based bio...

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressWALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 - Apellis Pharmaceu...

Investigation Alert: Johnson Fistel, LLP Explores Potential Violations by Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied DigitalSan Diego-based shareholder rights law firm, Johnson Fistel, LLP, has annou...

Apellis Pharmaceuticals secures $475 million credit facility to refinance existing debtWALTHAM, Mass., May 14, 2024 - Apellis Pharmaceuticals, Inc. has announced its entry into a non-dilutive, senior secured credit faci...

Apellis Pharmaceuticals, Inc. recently announced that they will be presenting 14 abstracts, including 11 oral presentations, at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Th...

WALTHAM, Massachusetts, April 26th, 2024 Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announces a significant step forward in its journey, redefining the dynamism of the pharmaceutical sector. The European Medicines Age...

Apellis Pharmaceuticals Inc. made an exciting announcement today regarding the approval of equity awards for a new employee, underlining the company s ongoing efforts to attract and retain top talent. The grant of equit...

By Date: Today s DateWALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a blow to its plans for the marketing authorization of intravitreal pegcetacoplan in the European Union (EU) for the treatment...

Apellis Pharmaceuticals, Inc., a leading biopharmaceutical company, recently announced its preliminary fourth-quarter and full-year net product revenues for 2023. The figures reveal significant success in the sales of i...

Apellis Pharmaceuticals recently made an exciting announcement regarding the approval of equity awards for two new employees. These inducement grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), were designe...

Apellis Pharmaceuticals Approves Inducement Grants for New Employees, Impacts Share PerformanceApellis Pharmaceuticals, a leading biopharmaceutical company, recently announced the approval of equity awards for four new...

Apellis Pharmaceuticals Bolsters Workforce with Equity Inducement Awards: What It Means for Company SharesWALTHAM, Mass., Nov. 06, 2023 - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has recently announced the approval...